Digges, Madeline, Hussein, Akram, Wilcock, Andrew, Crawford, Gregory B., Boland, Jason W., Agar, Meera R., Sinnarajah, Aynharan, Currow, David C. and Johnson, Miriam J.
(2018)
Pharmacovigilance in hospice/palliative care: net effect of haloperidol for nausea or vomiting.
Journal of Palliative Medicine, 21
(1).
pp. 37-43.
ISSN 1557-7740
Full text not available from this repository.
Abstract
Background: Haloperidol is widely prescribed as an antiemetic in patients receiving palliative care, but there is limited evidence to support and refine its use.
Objective: To explore the immediate and short-term net clinical effects of haloperidol when treating nausea and/or vomiting in palliative care patients.
Design: A prospective, multicenter, consecutive case series.
Setting/Subjects: Twenty-two sites, five countries: consultative, ambulatory, and inpatient services.
Measurements: When haloperidol was started in routine care as an antiemetic, data were collected at three time points: baseline; 48 hours (benefits); day seven (harms). Clinical effects were assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE).
Results: Data were collected (May 2014–March 2016) from 150 patients: 61% male; 86% with cancer; mean age 72 (standard deviation 11) years and median Australian-modified Karnofsky Performance Scale 50 (range 10–90). At baseline, nausea was moderate (88; 62%) or severe (11; 8%); 145 patients reported vomiting, with a baseline NCI CTCAE vomiting score of 1.0. The median (range) dose of haloperidol was 1.5 mg/24 hours (0.5–5 mg/24 hours) given orally or parenterally. Five patients (3%) died before further data collection. At 48 hours, 114 patients (79%) had complete resolution of their nausea and vomiting, with greater benefit seen in the resolution of nausea than vomiting. At day seven, 37 (26%) patients had a total of 62 mild/moderate harms including constipation 25 (40%); dry mouth 13 (21%); and somnolence 12 (19%).
Conclusions: Haloperidol as an antiemetic provided rapid net clinical benefit with low-grade, short-term harms.
| Item Type: |
Article
|
| RIS ID: |
https://nottingham-repository.worktribe.com/output/902156 |
| Additional Information: |
© 2018 Mary Ann Liebert, Inc. publishers All rights reserved. Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/10.1089/jpm.2017.0159 |
| Keywords: |
Haloperidol; Nausea; Palliative care; Pharmacovigilance; Symptom control; Vomiting |
| Schools/Departments: |
University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine > Division of Cancer and Stem Cells |
| Identification Number: |
10.1089/jpm.2017.0159 |
| Depositing User: |
Eprints, Support
|
| Date Deposited: |
22 Jan 2018 09:54 |
| Last Modified: |
04 May 2020 19:24 |
| URI: |
https://eprints.nottingham.ac.uk/id/eprint/49227 |
Actions (Archive Staff Only)
 |
Edit View |
Tools
Tools
